Janssen’s Covid-19 vaccine is intended for people who have no access to other authorised or approved shots or are clinically appropriate. Credit: Mohammad Shahhosseini on Unsplash.

The US Food and Drug Administration (FDA) has limited the authorised use of the Janssen’s Covid-19 vaccine to people aged 18 years and above.

With the US COVID-19 Vaccine Fact Sheet update, the vaccine is intended for use in people for whom no other authorised or approved Covid-19 vaccines are available or clinically appropriate.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

It is also indicated for individuals who choose the Janssen’s vaccine because they would not otherwise get a Covid-19 vaccine.

The latest move comes after the regulatory agency carried out an updated assessment and evaluation of cases reported and concluded that the thrombosis risk with thrombocytopenia syndrome (TTS) warrants limited usage of the shot.

TTS causes rare blood clots along with reduced blood platelet levels. 

The development of such symptoms was reported nearly one to two weeks after administering the Janssen’s Covid-19 vaccine.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Furthermore, the FDA noted that the established and potential benefits of the shot to prevent Covid-19 outweigh the known and potential risks in adults.

The updated authorisation for the use of the vaccine and a warning statement on TTS risk were included in the Fact Sheet for Healthcare Providers Administering Vaccine. 

Additionally, the Fact Sheet for Recipients and Caregivers now reflects revised authorised use of the shot with data on blood clot risk with reduced blood platelet levels added.

FDA Center for Biologics Evaluation and Research director Peter Marks said: “We’ve been closely monitoring the Janssen COVID-19 Vaccine and occurrence of TTS following its administration and have used updated information from our safety surveillance systems to revise the EUA. 

“The agency will continue to monitor the safety of the Janssen Covid-19 vaccine and all other vaccines, and as has been the case throughout the pandemic, will thoroughly evaluate new safety information.”